Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $15

Benzinga Newsdesk www.benzinga.com Positive 52.4%

Neg 0% Neu 0% Pos 52.4%

Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the price target from $9 to $15.